Advertisement
Canada markets open in 5 hours 23 minutes
  • S&P/TSX

    21,714.54
    -297.08 (-1.35%)
     
  • S&P 500

    5,035.69
    -80.48 (-1.57%)
     
  • DOW

    37,815.92
    -570.17 (-1.49%)
     
  • CAD/USD

    0.7262
    +0.0001 (+0.01%)
     
  • CRUDE OIL

    80.79
    -1.14 (-1.39%)
     
  • Bitcoin CAD

    78,739.41
    -8,323.58 (-9.56%)
     
  • CMC Crypto 200

    1,238.90
    -100.16 (-7.48%)
     
  • GOLD FUTURES

    2,295.70
    -7.20 (-0.31%)
     
  • RUSSELL 2000

    1,973.91
    -42.12 (-2.09%)
     
  • 10-Yr Bond

    4.6860
    +0.0720 (+1.56%)
     
  • NASDAQ futures

    17,459.75
    -111.50 (-0.63%)
     
  • VOLATILITY

    15.84
    +0.19 (+1.21%)
     
  • FTSE

    8,160.75
    +16.62 (+0.20%)
     
  • NIKKEI 225

    38,274.05
    -131.61 (-0.34%)
     
  • CAD/EUR

    0.6807
    +0.0005 (+0.07%)
     

Q1 Earnings Review

Pre-market futures are up slightly at this hour. Markets look to rebound off a three-day losing streak on the S&P 500 and Nasdaq; the blue-chip Dow outperformed the field yesterday, closing +0.17%. Major indices are all lower over the past month, from -1.7% (tech-heavy Nasdaq) to -2.9% (small-cap Russell 2000). Year to date, only the Russell is back in the red — the Dow is +0.3%, the S&P is +6.7% and the Nasdaq is +7.2%. Late March highs — including all-time S&P levels — have given way to profit-taking and existential concerns.

Q1 earnings season rolls along. Abbott Laboratories ABT outperformed expectations on both top and bottom lines in its Q1 report ahead of today’s opening bell. Earnings of 98 cents per share (excluding specific items) surpassed the Zacks consensus by 2 cents (though down from the $1.03 per share reported a year ago), while quarterly sales came in at $10.0 billion even, nicely ahead of the $9.85 billion projected. Full-year earnings guidance narrowed in-line with previous consensus. The Big Pharma company only has one earnings miss in the past five years, and brought a Zacks Rank #2 (Buy) into its earnings release.

Dow component Travelers Insurance TRV, on the other hand, was mixed: earnings of $4.69 per share missed the expected $4.75 by -1.26%, marking the company’s third earnings miss in the past four quarters. Revenues, however, inched past estimates by +0.05% to $11.19 billion in the quarter. This is the fourth-straight quarter of better-than-expected revenue growth. Shares had been up +17% year to date, but shares are selling off -5% before today’s open.

We’ll also see the latest Beige Book release from the Fed this afternoon at 2pm. In the March edition, we saw increased economic activity overall, with only Philadelphia reporting a down-tick for the period. We noted consumer spending down slightly, with price sensitivity at restaurants, hotels, etc. The labor market was up slightly as of last month, and most of this data bears out in subsequent economic prints, from the Fed and elsewhere.

After today’s close, we’ll get new earnings reports from Las Vegas Sands LVS and CSX Corp. CSX, as well as Zacks Rank #2-rated SL Green Realty SLG, a New York-based office REIT. Thursday afternoon, we’ll get the first of the formerly-referred-to FANG stocks when Zacks Rank #3 (Hold)-rated Netflix NFLX, while next week brings us the next tranche of headline-grabbing firms, including Tesla TSLA on Tuesday, Meta META Wednesday and Alphabet GOOGL Thursday.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Abbott Laboratories (ABT) : Free Stock Analysis Report

CSX Corporation (CSX) : Free Stock Analysis Report

ADVERTISEMENT

Netflix, Inc. (NFLX) : Free Stock Analysis Report

The Travelers Companies, Inc. (TRV) : Free Stock Analysis Report

Las Vegas Sands Corp. (LVS) : Free Stock Analysis Report

SL Green Realty Corporation (SLG) : Free Stock Analysis Report

Tesla, Inc. (TSLA) : Free Stock Analysis Report

Alphabet Inc. (GOOGL) : Free Stock Analysis Report

Meta Platforms, Inc. (META) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research